Oxin Darou Pars

Oxin Darou Pars is an Iranian pharmaceutical company specializing in the development and manufacture of high-tech medicinal products. The company focuses significantly on neurology, particularly treatments for multiple sclerosis, including glatiramer acetate and fingolimod. Beyond neurology, Oxin Darou Pars produces a range of medications for oncology and cardiovascular health. They operate modern manufacturing facilities that adhere to international GMP standards to ensure the quality of their specialized generics and biosimilars. The company plays a vital role in the Iranian healthcare sector by providing affordable access to complex therapies. Their strategic focus on high-value, difficult-to-manufacture drugs positions them as a leader in the domestic specialized pharmaceutical market.